戻る Agenda
Session 9 Track 2A: Scientific Communication Strategy
Session Chair(s)
David B. Clemow, PhD
Advisor, Scientific Communications Information Strategy
Eli Lilly and Company, United States
This session will provide insights and best practices for creating and organizing consistent messaging across regulatory submission and publication documents, with a focus on mapping clinical trial data outputs to key messages and downstream disclosure documents. The role of scientific communications (medical writing) in medical key message development, knowledge management, and dissemination will be discussed, with suggestions for process integration with other medical functions to aid with synergy. These topics will also be reviewed more holistically regarding the overall role of medical writers involvement in scientific communications strategy, based upon insights from the DIA Medical Writing Competency Model.
Learning Objective : At the conclusion of this session, participants should be able to:
Speaker(s)
Submission Communication Strategy Document to Drive Consistent Messaging in CTD Dossiers
David Brown, MA, MSc
AstraZeneca Pharmaceuticals, United States
Therapy Area Leader, Medical Communications
Medical and Scientific Key Message Development, Knowledge Management, and Dissemination
David B. Clemow, PhD
Eli Lilly and Company, United States
Advisor, Scientific Communications Information Strategy
Medical Writing Leadership in Scientific Communications Strategy
Michael Bourque, MS
Synchrogenix, a Certara Company, United States
Director of Global Submissions